Werewolf Therapeutics (HOWL) News Today

Werewolf Therapeutics (NASDAQ:HOWL) Stock Price Down 3.6%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Werewolf Therapeutics in a research report issued to clients and investors on Monday, August 19th. Leerink Partnrs analyst D. Graybosch forecasts that the compan

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Equities research analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Werewolf Therapeutics in a note issued to investors on Monday, August 19th. Leerink Partnrs analyst D. Graybosch expects that the company w

Janus Henderson Group PLC acquired a new position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,688,054 shares of the company's stock, valued at

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 1,050,000 shares, a growth of 55.1% from the June 30th total of 677,100 shares. Based on an average daily trading volume, of 313,000 shares, the short-interest ratio is presently 3.4 days. Currently, 3.5% of the shares of the company are sold short.

HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a report on Tuesday.

JMP Securities restated a "market outperform" rating and set a $12.00 price target on shares of Werewolf Therapeutics in a report on Wednesday.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the target of a large growth in short interest in May. As of May 31st, there was short interest totalling 469,100 shares, a growth of 26.1% from the May 15th total of 372,000 shares. Based on an average daily trading volume, of 188,100 shares, the days-to-cover ratio is presently 2.5 days. Approximately 1.6% of the shares of the stock are sold short.

Wedbush reaffirmed an "outperform" rating and set a $9.00 target price on shares of Werewolf Therapeutics in a research report on Monday.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totalling 372,000 shares, a decline of 10.3% from the April 30th total of 414,500 shares. Based on an average trading volume of 185,300 shares, the days-to-cover ratio is currently 2.0 days. Approximately 1.3% of the company's stock are short sold.

Wedbush restated an "outperform" rating and issued a $9.00 target price on shares of Werewolf Therapeutics in a research report on Monday.

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totalling 472,000 shares, an increase of 9.3% from the March 15th total of 432,000 shares. Currently, 1.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 240,200 shares, the days-to-cover ratio is currently 2.0 days.

JMP Securities started coverage on Werewolf Therapeutics in a research report on Wednesday. They issued a "market outperform" rating and a $12.00 target price on the stock.

Werewolf Therapeutics (NASDAQ:HOWL) Trading 2.9% Higher